ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03102047
Recruitment Status : Not yet recruiting
First Posted : April 5, 2017
Last Update Posted : September 11, 2017
Sponsor:
Information provided by (Responsible Party):
NSABP Foundation Inc

Brief Summary:

This study is being done to look at the safety and response to the investigational drug durvalumab (MEDI4736) following chemo-radiation therapy for patients with MSS stage II to IV rectal cancer. Durvalumab recognizes specific proteins on the surface of cancer cells and triggers the immune system to destroy the cancer cells. The chemoRT portion of the treatment will be completed just before the course of durvalumab is initiated.

In order to learn more about certain characteristics of rectal cancer tumors, this study includes special research tests using samples from diagnostic tumors, a tissue sample from tumors removed during surgery, fresh tumor samples from an area where the cancer has recurred, and blood samples.


Condition or disease Intervention/treatment Phase
Rectal Cancer Drug: durvalumab Phase 2

Detailed Description:

The FR-2 study is designed as a phase II, open label, single arm study in patients with microsatellite stable (MSS) stages II-IV rectal cancer, to assess the activity of PD-L1 inhibition with durvalumab (MEDI4736) monotherapy after standard chemo-radiotherapy (chemoRT). The study's primary aim is to determine the safety and efficacy of durvalumab immediately following chemoRT in patients undergoing subsequent surgery with stage II-IV rectal cancer.

One dose of durvalumab will be given every 2 weeks for four total doses beginning within 3-7 days of completing chemoRT. Surgery for all patients must occur within 8−12 weeks of the final dose of RT. Adjuvant chemotherapy after surgical recovery is at the discretion of the treating physician.

During a safety run-in, the first 6 patients will be closely followed for 30 days after last dose of durvalumab without further accrual of patients. Patients will receive durvalumab (750mg IV infusion once every 2 weeks) for 4 total doses. No other concurrent anti-neoplastic medications or treatments aside from standard supportive care will be allowed during the durvalumab treatment phase.

The safety run-in portion of the study will proceed to full enrollment at the proposed study therapy dose, (750 mg IV infusion every 2 weeks), if one or less dose-limiting toxicity (DLT) or significant safety concern attributable to durvalumab is identified during the observation period of the first 6 patients. If there are two or more DLTs, accrual to the study will stop with reassessment of the protocol.

A total of 47 patients will be enrolled in this study for a sample size of 41 surgically evaluable patients.

Required tissue and blood samples will be collected at specific time points and submitted for correlative science studies. Optional tumor and blood samples will be collected from consenting patients upon disease recurrence or progression.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 47 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study to Assess the Activity of PD-L1 Inhibition With Durvalumab (MEDI4736) After Chemo-Radiotherapy in Patients With Stage II-IV Microsatellite Stable (MSS) Rectal Cancer
Estimated Study Start Date : October 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Durvalumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: durvalumab
IV infusion once every 2 weeks for 4 total doses
Drug: durvalumab
Within 3−7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)
Other Name: MEDI4736



Primary Outcome Measures :
  1. Median Neoadjuvant Rectal (NAR) Score [ Time Frame: From the beginning of the study to time of surgical resection, assessed over an estimated 12 weeks ]
    Compare Median Neoadjuvant Rectal (NAR) Score to historic control using the Wilcoxon test


Secondary Outcome Measures :
  1. Pathologic complete response rate to study therapy [ Time Frame: At the time of surgical resection ]
    Pathologic Complete response rate ( pCR) (ypT0 and ypN0) of primary rectal cancer and regional nodes determined by pathological examination

  2. Clinical complete response rate to study therapy [ Time Frame: From one week prior to surgical resection up to time of surgical resection ]
    Clinical complete response rate cCR (ycT0) determined by the clinical absence of the primary tumor via digital rectal exam and proctoscopic exam

  3. Rate of negative circumferential margin [ Time Frame: At the time of surgical resection ]
    Rate of negative circumferential margin in surgical resection specimens

  4. Sphincter function in patients with sphincter preserving surgery [ Time Frame: From the time of surgical resection to 30 days after surgery ]
    Sphincter function as determined by number of adverse events related to bowel control

  5. Severity of post-operative complications [ Time Frame: From time of surgical resection to within 30 days post-operation ]
    Surgical complications that result in re-hospitalizations or death

  6. Objective response rate to study therapy [ Time Frame: From date of randomization through study therapy, generally 8-12 weeks ]
    Objective response rate (ORR) determined by RECIST 1.1 criteria

  7. Duration of study therapy [ Time Frame: From date study therapy begins to completion of study therapy, generally 8-12 weeks ]
    Duration of study therapy in selected patients

  8. Frequency of adverse events assessed by CTCAE 4.0 [ Time Frame: From beginning of study therapy to 90 days after last dose of study therapy ]
    Frequency of adverse events categorized using the NCI Common Terminology Criteria for Adverse Events version 4.0



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The ECOG performance status must be 0 or 1
  • Patients with biopsy-proven adenocarcinoma, stage II- IV rectal cancer.
  • The tumor must have been determined to be mismatch repair proficient or microsatellite stable through CLIA approved testing (Immunohistochemistry [IHC], polymerase chain reaction [PCR], or Next-Generation Sequencing [NGS] assays).
  • Patients must be candidates for planned surgical resection of their primary rectal cancer 8 - 12 weeks after completion of neoadjuvant chemoRT, even if stage IV.
  • Planned neoadjuvant chemoRT treatment must conform to NCCN guidelines.
  • Baseline staging prior to treatment initiation must be obtained. If stage IV, there must be documentation by PET/CT scan, CT scan, or MRI, that the patient has evidence of measurable distant disease per RECIST 1.1. Note: Patients with stage IV disease should have limited but measurable metastatic disease (one or two organs involved e.g., liver and lung) and primary tumor deemed resectable.
  • Blood counts performed within 4 weeks prior to study entry must meet the following criteria:

    • ANC must be greater than or equal to 1500/mm3
    • Platelet count must be greater than or equal to 75,000/mm3; and
    • Hemoglobin must be greater than or equal to 9 g/dL.
  • Adequate hepatic function performed within 4 weeks prior to study entry must be met:

    • Total bilirubin must be less than or equal to 1.5 x ULN (upper limit of normal) for the lab unless the patient has a bilirubin elevation greater than 1.5 x Upper limit of normal (ULN) to 3 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and
    • AST and ALT must be less than or equal to 2.5 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be less than or equal to 5 x ULN.
  • Adequate renal function within 4 weeks of study entry, defined as serum creatinine less than or equal to 1.5 x ULN for the lab. (If creatinine is 1.0-1.5 x ULN, the creatinine clearance should be greater than 40 mL/min per Cockcroft-Gault formula (Cockcroft-Gault 1976), or by 24-hour urine collection for determination of creatinine clearance.)
  • Patients with reproductive potential (male/female) must agree to use accepted and highly effective methods of contraception while receiving durvalumab, and for at least 3 months after the last dose of durvalumab.
  • Female patients must either be of non-reproductive potential (i.e., post-menopausal by history: greater than or equal to 60 years old and no menses for greater than or equal to 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.

Exclusion Criteria:

  • Diagnosis of anal or small bowel carcinoma.
  • Histopathology other than adenocarcinoma, e.g., sarcoma, lymphoma, carcinoid.
  • Previous therapy with any PD1 or PD-L1 inhibitor (including durvalumab) for any malignancy.
  • Completion of pelvic radiotherapy treatment for this current rectal cancer or any prior pelvic radiotherapy (e.g., prior prostate or cervical cancer therapy).
  • Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days after receiving the last dose of durvalumab.
  • Acute or chronic hepatitis B or hepatitis C.
  • Known history of human immunodeficiency virus (HIV) or acquired immunodeficiency-related (AIDS) illnesses.
  • History of brain metastases, uncontrolled spinal cord compression, carcinomatous meningitis, or new evidence of brain or leptomeningeal disease.
  • Active infection or chronic infection requiring chronic suppressive antibiotics.
  • History of allogeneic organ transplantation.
  • Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
  • Active or prior history of autoimmune or inflammatory condition requiring ongoing immunosuppressive medications. This specifically includes use of immunosuppressive medication within 28 days before the first dose of durvalumab with the exceptions of intranasal corticosteroids or systemic corticosteroids at physiological doses, which do not exceed 10mg/day of prednisone or an equivalent corticosteroid.
  • Any of the following cardiac conditions:

    • Documented NYHA Class III or IV congestive heart failure
    • Myocardial infarction within 6 months prior to study entry
    • Unstable angina within 6 months prior to study entry
    • Symptomatic arrhythmia
    • Prolonged QTc greater than or equal to 470 ms. If QTc greater than or equal to 470ms, confirmation of eligible QTc requires mean calculation from 2 additional electrocardiograms (ECGs) 2−5 minutes apart using Fridericia's Correction Formula (mean less than 470 ms).
  • Uncontrolled high blood pressure defined as systolic BP greater than or equal to 150 mmHg or diastolic BP greater than or equal to 100 mmHg with or without anti-hypertensive medication. Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.
  • Ongoing or active gastritis or peptic ulcer disease.
  • Active bleeding diatheses which in the opinion of the treating physician poses a significantly increased operative risk.
  • Known history of previous diagnosis of tuberculosis.
  • History of hypersensitivity to durvalumab or any excipient.
  • Known history of active pneumonia, pneumonitis, symptomatic interstitial lung disease, or definitive evidence of interstitial lung disease described on CT scan, MRI, or chest x-ray in asymptomatic patients; dyspnea at rest requiring current continuous oxygen therapy.
  • Other malignancies unless the patient is considered to be disease-free and has completed therapy for the malignancy greater than or equal to 12 months prior to study entry. Patients with the following cancers are eligible if diagnosed and treated within the past 12 months: carcinoma in situ of the cervix, colorectal carcinoma in situ, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
  • Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements, or interfere with interpretation of study results.
  • Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed within 14 days prior to study entry according to institutional standards for women of childbearing potential.)
  • Use of any investigational agent within 4 weeks prior to study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03102047


Contacts
Contact: Diana Gosik, RN, BS 412-339-5333 diana.gosik@nsabp.org

Sponsors and Collaborators
NSABP Foundation Inc
Investigators
Principal Investigator: Norman Wolmark, MD NSABP Foundation Inc

Responsible Party: NSABP Foundation Inc
ClinicalTrials.gov Identifier: NCT03102047     History of Changes
Other Study ID Numbers: NSABP FR-2
ESR-15-11477 ( Other Identifier: AstraZeneca )
First Posted: April 5, 2017    Key Record Dates
Last Update Posted: September 11, 2017
Last Verified: March 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by NSABP Foundation Inc:
microsatellite stable
MSS
durvalumab
NSABP

Additional relevant MeSH terms:
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs